Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Working with many rare forms of blood disorders, the Stanford Hematology Program brings together a multispecialty team of experts dedicated to treating leukemia as well as other benign and malignant hematologic disorders.
Offering state-of-the-art chemotherapy protocols for leukemia and other hematologic malignancies, as well as working seamlessly with Stanford's highly-acclaimed Blood and Marrow Transplant Program, the Hematology Program strives to assure the best possible outcome for patients. Our goal is to improve the survival and quality of life of patients, and Stanford hematologists were instrumental in the development of the National Comprehensive Cancer Network (NCCN) guidelines for the management of hematologic malignancies.
State-of-the-art surgical techniques to address metastatic tumors
Advanced minimally invasive surgery, including use of robotics to enhance complex procedures, minimize patient stays, and speed recovery times
Intraoperative radiation therapy (IORT), which delivers high-dose radiation directly to a patient's tumor site during surgery
New and investigational treatments, including PARP inhibitors, immunotherapies such as dendritic cell therapy, and ovarian cancer vaccines
Fertility-conserving surgery and advanced assisted reproductive technology to help maximize your childbearing options
Immunotherapy (also called biological therapy, biological response modifier therapy, or biotherapy) is designed to boost the body's immune system in order to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Doctors and researchers have found that the immune system might also be able to both determine the difference between healthy cells and cancer cells in the body, and to eliminate the cancer cells.
Beverly Mitchell, MD, Director of the Stanford Cancer Institute, talks about why she became a doctor and what she loves about her field.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Please fax the Medical Record Release Form to your new patient coordinator. The medical release form is an authorization form for external facilities to release medical records to Stanford Health Care.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
HOW TO REFER
Fax a referral form with supporting documentation to 650-320-9443.
Please note, though this form is from Stanford Health Care, it is also used for all Cancer Center referrals.